Inclusion Criteria:

          1. Patient age must be >= 18 years

          2. Patients must understand and provide written informed consent and Health Insurance
             Portability and Accountability Act of 1996 (HIPAA) authorization authorization prior
             to initiation of any study-specific procedures

          3. Patients must have recurrence of histologically-proven glioblastoma or gliosarcoma,
             World Health Organization (WHO) grade IV that is surgically resectable.

          4. The patient's surgeon thinks that they can resect at least 500 mg of tumor.

          5. Patient must have Karnofsky Performance Scale (KPS) score >=70

          6. Patient must have an estimated life expectancy ≥ 3 months

          7. Patients may enroll independent of number of prior therapies or cumulative doses of
             prior therapies, but must have received appropriate prior therapy for GBM at time of
             initial diagnosis, including radiation therapy.

          8. Patient must have adequate bone marrow function, renal function, and hepatic function
             as defined below:

             Adequate bone marrow function:

               1. absolute neutrophil count (ANC) >= 1,500/μL

               2. Platelets >= 100,000/μL

             Adequate hepatic function:

               1. total bilirubin <= 1.5x institutional upper limit of normal

               2. Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT)
                  <= 2.5x institutional upper limit of normal

               3. Alanine aminotransferase (ALT) / serum glutamic-pyruvic transaminase (SGPT) <=
                  2.5x institutional upper limit of normal

             Adequate renal function:

             a. creatinine <= 1.5x institutional upper limit of normal OR creatinine clearance >=
             60 mL/min/1.73 m2

          9. Must be able to undergo MRI scans for tumor evaluation.

         10. Women of child-bearing potential must have a negative pregnancy test (urine or serum)
             within 7 days prior to surgery.

             The effects of study drugs, either individually or their combination on the developing
             human fetus are unknown. For this reason, women of child-bearing potential and men
             must agree to use adequate contraception prior to study entry and for the duration of
             study participation and for 3 months after completion of study drug administration.
             The use of adequate contraception may be longer than 3 months depending on the drugs
             used and the FDA-approved labeling in cases of recommendation for contraception.
             Adequate contraception may include hormonal contraception, barrier method (condom,
             contraceptive sponge, diaphragm or ring), intrauterine device (IUD), tubal ligation,
             vasectomy and abstinence. Should a woman become pregnant (or suspect that she is
             pregnant) while she or her partner is participating in this study, she should inform
             her treating physician immediately. Men treated or enrolled on this protocol must also
             agree to use adequate contraception prior to the study, for the duration of study
             participation, and 3 months after completion of study drug administration. Patient
             must not be a woman who is currently pregnant, due to the potential for teratogenic or
             abortifacient effects of study drugs, either alone or in combination. Because there is
             an unknown but potential risk of adverse events in nursing infants secondary to
             treatment of the mother with study drugs, lactating women who are breastfeeding should
             discontinue breastfeeding if the mother is treated with any study drug.

         11. Patients must not have New York Heart Association (NYHA) Grade II or greater
             congestive heart failure

         12. Patients must not have history of myocardial infarction or unstable angina within 12
             months prior to study enrollment.

        Exclusion Criteria:

          1. Patient who has been treated with any chemotherapy or radiotherapy ≤4 weeks prior to
             date of study registration. Exceptions to this include: must be ≥ 23 days from last
             dose of temozolomide (TMZ), must be ≥ 6 weeks from last dose of nitrosurea.

          2. Patient who has not recovered to grade 1 or baseline from the adverse effects of prior
             radiotherapy or chemotherapy.

          3. Patient who is < 12 weeks from initial course of radiation

          4. Patients with multifocal tumor, primarily infratentorial or posterior fossa tumor, or
             leptomeningeal dissemination of tumor.

          5. Patient with any other active malignancy besides GBM, excluding non-melanomatous skin
             cancer, or carcinoma in situ of the cervix, prostate, or breast, unless patient has
             been disease-free/in remission for >=2 years prior to date of study enrollment

          6. Patients known to be HIV-positive. HIV testing is not required for study
             participation.

          7. Uncontrolled concurrent illness including psychiatric illness, or situations that
             would limit compliance with the study requirements or the ability to willingly give
             written informed consent.